All News
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Alendronate Atypical Fractures Back In Court
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.
Read Article
Manual labor jobs have more work disability in #PsA. 564 PsA pts, 29% were Blue collar; 71% White Collar. BCol (80% male) had more work disability at baseline (84% vs 28%; p < 0.01). Occupation did not influence DAS28-CRP remission at 1 yr, suggesting Rx response unaffected by… https://t.co/A9E5WZqIwu https://t.co/8PelrtpXco
Dr. John Cush RheumNow ( View Tweet)
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush RheumNow ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush RheumNow ( View Tweet)
Alendronate Atypical Fractures Back In Court
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.… https://t.co/DWXsFyzfWs https://t.co/HhROUArYBE
Dr. John Cush RheumNow ( View Tweet)
Economic and Mental Health Burden of Rheumatoid Arthritis
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life.… https://t.co/UpxHJSG6BL https://t.co/luPp1gjlRA
Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
Inadequate Zoster Vaccination in Immunocompromised Patients
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.… https://t.co/EV24CQazex https://t.co/jiTuWQySgs
Dr. John Cush RheumNow ( View Tweet)
Is EBV relevant? It's certainly been linked to the etiol of SLE, RA, Sjögrens, & MS. Ronbinson et al suggests "EBV infection as a potentiator of autoimmune rheumatic diseases" and if Rx targeting of EBV may work in EBV-associated autoimmune diseases. https://t.co/bi630VvHTx https://t.co/tKYtwePaTu
Dr. John Cush RheumNow ( View Tweet)
NEJM Review Article on
"Cryoglobulinemia — One Name for Two Diseases "
(sign up for free read)
https://t.co/RFLKBeze3a https://t.co/eA3SLmPMdj
Dr. John Cush RheumNow ( View Tweet)
EULAR has announced its new, open access journal - EULAR Rheumatology Open (ERO) https://t.co/PWPXZ4H2Ku https://t.co/7kHcUpLFXD
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Links:
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush RheumNow ( View Tweet)
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Men and Women Process Pain Differently
Men and women experience pain relief differently; a new study may help explain why women have more chronic pain and are less responsive to opioid treatments.
https://t.co/MYWAZnqGmA https://t.co/TxofSlsI4M
Dr. John Cush RheumNow ( View Tweet)
Health Disparities in DMARD Use in RA
A UK study shows biological and targeted synthetic DMARD (b/tsDMARDs) use in newly diagnosed rheumatoid arthritis (RA) varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
https://t.co/t7O99FM7fQ https://t.co/CtvfblpPUo
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular health (CVH) is critical in arthritis care. NHANES study 5919 arthritis pts finds 10-point incr, in CVH score yielded significantly lower all-cause mortality risk (adj HR 0.72; 0.67–0.79); best results with OA/DJD, more than inflammatory arthritis.… https://t.co/etBbH7bH1D https://t.co/1is2VlT5sl
Dr. John Cush RheumNow ( View Tweet)
ACR and Congress Address “Damaging” Cuts to Medicare MD Payments
The ACR commended the 233 bipartisan representatives who signed a letter urging House Speaker Mike Johnson (R-LA) and Minority Leader Hakeem Jeffries (D-NY) to support legislative action to address “damaging”… https://t.co/nVhRAeBf7y https://t.co/GwQTAi7GR1
Dr. John Cush RheumNow ( View Tweet)
